GlobeNewswire

ObsEva Announces First Quarter 2021 Financial Results and Business Update

Share

-Yselty® for uterine fibroids: US New Drug Application submissionplanned in Q3:21; European marketing approval recommendation anticipated in Q4:21-

-Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21-

-Ebopiprant: Phase 2b dose ranging study planned to initiate in Q4:21 based on positive Phase 2a proof of concept-

-Actively pursuing new indications and partnerships to maximize value of pipeline candidates-

GENEVA, Switzerland and BOSTON, MAMay6, 2021 – ObsEva SA (NASDAQ: OBSV)(SIX: OBSN) (ObsEva or the Company), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the quarter ended March 31, 2021 and provided a business update.

“The outset of 2021 was marked with a prioritization of capitalization and commercialization, and we have made significant progress on both fronts,” said Brian O’Callaghan, CEO of ObsEva. “In the first quarter of 2021, we raised over $60 million in gross equity proceeds, providing the capital needed to continue to advance our pipeline, reach multiple clinical and regulatory milestones, and execute on our well-defined strategic plan. On the commercialization front, we have created significant optionality and momentum with numerous negotiations that have reached an advanced stage. We plan to build on this momentum and select the best potential partners and strategies for each of our programs and look forward to providing additional updates in due course.”

Anticipated Milestones

ObsEva aims to achieve the following key clinical and regulatory objectives in 2021:

  • Yselty for uterine fibroids: NDA submission (Q3:21); MAA approval recommendation (Q4:21)
  • Yselty for endometriosis: Phase 3 EDELWEISS 3 primary endpoint readout (Q4:21)
  • Ebopiprant for treatment of preterm labor: Phase 2b dose ranging study initiation in EU/Asia (Q4:21)

Pipeline Update

Yselty for the treatment of uterine fibroids and endometriosis

  • Yselty for Uterine Fibroids:   ObsEva is developing Yselty, an oral GnRH receptor antagonist with the potential to treat more women due to its potential best-in-class efficacy, a favorable tolerability profile and unique, flexible dosing options for the treatment of uterine fibroids. Following the European Medicine Agency’s (EMA) validation of the marketing authorization application (MAA), a major milestone toward making Yselty available in the EU, the Company continues to work closely with the EMA to achieve marketing approval, with an approval recommendation from the Committee for Medicinal Products for Human Use (CHMP) projected in Q4:2021 and formal product approval expected to follow shortly thereafter. The Company is also working to submit a U.S. New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA), projected in Q3:2021, that will include the Week 76 post-treatment follow-up results from the Phase 3 PRIMROSE 1 (US only; n=574) and PRIMROSE 2 (Europe and US; n=535) clinical studies. In addition, the Company recently announced commencement of an observational study (PRIMROSE 3) of bone mineral density in women who completed at least 20 weeks of treatment in either of the PRIMROSE 1 or 2 studies.

  • Yselty for Endometriosis: The EDELWEISS 3 study in the EU is progressing as planned, with randomization of patients recently completed and primary endpoint data expected in Q4:2021. The ongoing Phase 3 EDELWEISS 3 study (Europe and US) is designed to enroll approximately 450 patients with endometriosis-associated pain, with a co-primary endpoint of response on both dysmenorrhea (menstrual pain) and non-menstrual pelvic pain. The study includes a 75 mg once-daily dose without hormonal ABT (1 mg estradiol / 0.5mg norethindrone acetate), and a 200 mg once-daily dose in combination with hormonal ABT. Subjects who have completed the initial six-month treatment period will have the option to enter a six-month treatment extension.

Ebopiprant for Treatment of Preterm Labor:   Preparations are ongoing to initiate a Phase 2b clinical study in Q4:21. The Phase 2b dose ranging study will build on the recently announced PROLONG Phase 2a proof-of-concept study, which demonstrated early clinical efficacy and safety in pregnant women with spontaneous preterm labor. Given ebopiprant is currently the only known product in development for this indication and based on its innovative mechanism of action and positive topline data, the Company plans to discuss with European regulators a possible accelerated registration program based on a Phase 2b/3 adaptive design.    In parallel with development of ebopiprant in Europe and Asia, the Company is also actively evaluating the regulatory strategy for ebopiprant development in the United States, where there are currently no FDA-approved tocolytic medications available for treatment of preterm labor.

Nolasiban for In Vitro Fertilization:   ObsEva is also advancing nolasiban, an oral oxytocin receptor antagonist, to improve live birth rates in women undergoing in vitro fertilization.

Financial Update

Net loss for the quarter ending March 31, 2021 was $20.0 million, or $0.29 per share, compared with a net loss of $21.9 million, or $0.48 per share, for the quarter ending March 31, 2020. Research and development expenses were $15.5 million and general and administrative expenses were $4.2 million for the quarter ended March 31, 2021, compared with $17.2 million and $3.7 million, respectively, for the prior year quarter. The net loss for the quarter ended March 31, 2021 included non-cash expenses of $2.0 million for stock-based compensation, compared with $2.7 million for the prior year period.

As of March 31, 2021, ObsEva had cash and cash equivalents of $68.0 million, compared with $31.2 million as of December 31, 2020. On March 5, 2021, ObsEva entered into a Sale Agreement with SVB Leerink LLC (SVB Leerink) to offer and sell common shares having an aggregate offering price of up to $50 million from time to time through an at the market offering under which SVB Leerink will act as sales agent.

The first quarter 2021 financial report will be available in the financial reports section of the Company’s website.

To access the financial reports section of the Company’s website, please click [here].

To access the first quarter 2021 financial report directly, please click [here].

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan", "potential", "will", and other similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the potential therapeutic benefits and the clinical development of ObsEva’s product candidates, the potential for new indications for any of ObsEva’s product candidates, the timing of enrollment in and data from clinical trials, expectations regarding regulatory and development milestones, including the potential timing of regulatory submissions to the EMA and FDA, the timing of and ObsEva’s ability to obtain and maintain regulatory approvals for its product candidates, the results of interactions with regulatory authorities and the potential to raise additional funds or enter into strategic partnerships in the future. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2020 and other filings ObsEva makes with the U.S. Securities and Exchange Commission. These documents are available on the Investors page of ObsEva’s website at http://www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617) 435-6602

Exhibit 99.3

Consolidated Statements of Comprehensive Loss

Three-month period
ended March 31,
(in USD ’000, except share and per share data) - unaudited20212020
Operating income other than revenue64
OPERATING EXPENSES
Research and development expenses(15,516)(17,188)
General and administrative expenses(4,191)(3,709)
Total operating expenses(19,707)(20,897)
OPERATING LOSS(19,701)(20,893)
Finance income62960
Finance expense(911)(1,011)
NET LOSS BEFORE TAX(19,983)(21,844)
Income tax expense(21)(19)
NET LOSS FOR THE PERIOD(20,004)(21,863)
Net loss per share
Basic(0.29)(0.48)
Diluted(0.29)(0.48)
Weighted Average Number of Shares Outstanding68,574,36445,725,561

Consolidated Balance Sheets

(in USD ’000) - unauditedMarch 31,
2021
December 31,
2020
ASSETS
Current assets
Cash and cash equivalents67,99831,183
Other receivables364397
Prepaid expenses4,6075,388
Total current assets72,96936,968
Non-current assets
Right-of-use assets1,2711,425
Furniture, fixtures and equipment133151
Intangible assets26,60826,608
Other long-term assets280295
Total non-current assets28,29228,479
Total assets101,26165,447
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities
Other payables and current liabilities5,70810,760
Accrued expenses10,62210,248
Current lease liabilities674696
Total current liabilities17,00421,704
Non-current liabilities
Non-current lease liabilities731952
Non-current borrowings25,41125,300
Post-employment obligations7,7908,218
Other long-term liabilities858919
Total non-current liabilities34,79035,389
Shareholders’ equity
Share capital6,9484,878
Treasury shares(938)(304)
Share premium414,483356,822
Reserves28,37326,353
Accumulated losses(399,399)(379,395)
Total shareholders’ equity49,4678,354
Total liabilities and shareholders’ equity101,26165,447

###

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Bavarian Nordic leverer vacciner til Englands beredskab i forbindelse med nye tilfælde af abekopper11.6.2021 19:12:35 CEST | pressemeddelelse

KØBENHAVN, Danmark, 11. juni 2021 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet for nylig er blevet anmodet af de engelske sundhedsmyndigheder, Public Health England (PHE) og Medicines and Health Products Regulatory Agency (MHRA), om at levere koppevaccinen IMVANEX® til vaccination i forbindelse med nye, udefrakommende tilfælde af abekopper i mennesker i England. To relaterede tilfælde er blevet bekræftet og er blevet indlagt på et hospital i Liverpool. Den ene er sandsynligvis blevet smittet i Afrika, hvorfra familien ankom et par dage inden sygdommen brød ud, mens den anden sandsynligvis er blevet smittet af det første tilfælde efter hjemkomsten. Abekopper er en sjælden, men alvorlig sygdom, der naturligt forekommer i det centrale og det vestlige Afrika. Sygdommen er beslægtet med den menneskelige koppesygdom, om end den er mindre alvorlig med en dødelighed, der er estimeret til at være fra 1-10% af tilfældene. IMVANEX (MVA-BN) er godkendt af Europa-Kommissionen til

Bavarian Nordic Assists Public Health England in Response to New Cases of Monkeypox11.6.2021 19:12:35 CEST | Press release

COPENHAGEN, Denmark, June 11, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company was recently engaged by Public Health England (PHE) and the Medicines and Health Products Regulatory Agency (MHRA) to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox in the UK. Two related cases were confirmed and admitted to a hospital in Liverpool. One was most likely infected in Africa, where the family arrived from a few days before onset of disease, and a sibling case most likely infected on UK soil by the first case. Monkeypox is a rare, but serious disease, which is endemic in Central and West Africa. The disease is quite similar to human smallpox, although it is less severe with an estimated fatality rate of 1-10%. IMVANEX (MVA-BN) is approved by the European Commission for active immunization against smallpox but has also received approval for monkeypox by the U.S. Food and Drug Administration (FDA) and Health Canada, as the only vaccine approved for

Minister Eriksen Søreide, Deputy Minister Ryabkov, and Deputy Secretary Hicks to Keynote 2021 Carnegie International Nuclear Policy Conference11.6.2021 17:30:00 CEST | Press release

Senior officials, leaders, and experts in defense, security, and nuclear policy convene for a 3-day conference on the most-pressing challenges in nuclear arms control, nonproliferation, deterrence, and security WASHINGTON, June 11, 2021 (GLOBE NEWSWIRE) -- From June 22-24, 2021, the Carnegie Endowment for International Peace will host its biennial International Nuclear Policy Conference virtually, including keynote addresses from: Ine Eriksen Søreide, Minister of Foreign Affairs for NorwaySergey Ryabkov, Deputy Minister of Foreign Affairs of the Russian FederationKathleen Hicks, U.S. Deputy Secretary of Defense Other speakers include: Izumi Nakamitsu, UN-Secretary-General and High Representative for Disarmament Affairs; Bishop Garrison, Senior Advisor to the U.S. Secretary of Defense for Human Capital and Diversity, Equity and Inclusion; Harry Harris, former U.S. ambassador to the Republic of Korea; and Maleeha Lodhi, former UN Representative for Pakistan. The full conference agenda ca

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS11.6.2021 16:20:00 CEST | Press release

Bid procedure, 2021-06-18BondsSWEDEN I/L BOND: 3114. SE0013748258. 2030-06-01 SWEDEN I/L BOND: 3111, SE0007045745, 2032-06-01 Bid date2021-06-18Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3114: 250 mln SEK +/-150 mln SEK 3111: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)3114: 250 mln SEK per bid 3111: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-06-22Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-06-11 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK TREASURY BILLS11.6.2021 16:20:00 CEST | Press release

Bid procedure, 2021-06-16BillsSWEDISH T-BILL: SE0014808747. 2021-09-15 SWEDISH T-BILL: SE0015244405, 2021-12-15 SWEDISH T-BILL: SE0015659529, 2022-03-16 Bid date2021-06-16Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SE0014808747: 1000 mln SEK +/-500 mln SEK SE0015244405: 1000 mln SEK +/-500 mln SEK SE0015659529: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)SE0014808747: 1000 mln SEK per bid SE0015244405: 1000 mln SEK per bid SE0015659529: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2021-06-18Delivery of billsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-06-11 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between t

CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER11.6.2021 16:20:00 CEST | Press release

Bid procedure, 2021-06-16CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of 2021-12-16 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2021-06-04 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2021-06-16Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SEK 250 million issued by the s

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS11.6.2021 16:20:00 CEST | Press release

Bid procedure, 2021-06-17BondsSWEDBANK HYPOTEK AB: 192. SE0010133207. 2023-03-15 STADSHYPOTEK AB: 1588, SE0011063015, 2024-03-01 SWEDISH COVERED BOND: 151, SE0013486156, 2030-06-12 SKANDINAVISKA ENSKILDA: 581, SE0013102043, 2026-12-16 LANSFORSAKRINGAR HYPOTEK: 519, SE0012324341, 2026-09-16 DANSKE HYPOTEK AB: 2512, SE0013877214, 2025-12-17 NORDEA HYPOTEK AB: 5533, SE0010442731, 2023-09-20 Bid date2021-06-17Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)192: 800 mln SEK +/-400 mln SEK 1588: 2000 mln SEK +/-1000 mln SEK 151: 700 mln SEK +/-350 mln SEK 581: 700 mln SEK +/-350 mln SEK 519: 600 mln SEK +/-300 mln SEK 2512: 200 mln SEK +/-100 mln SEK 5533: 1000 mln SEK +/-500 mln SEK Highest permitted bid volume (corresponding nominal amount)192: 800 mln SEK per bid 1588: 2000 mln SEK per bid 151: 700 mln SEK per bid 581: 700 mln SEK per bid 519: 600 mln SEK per bid 2512: 200 mln SEK per bid 5533: 1000 mln SEK per bid Lowest permitted bid volume